title: Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
abstract: OBJECTIVE
  We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as first-line treatment of metastatic breast cancer patients.
  
  
  METHODS
  We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m2 and gemcitabine 800 mg/m2 i.v. on days 1, 8, 15 every 28 days.
  
  
  RESULTS
  All patients were assessable for toxicity and 56 for efficacy. Overall response rate was 64.3% with 16.1% of complete responses and 48.2% of partial responses. Median survival was 22.10 months (95% CI: 15.53-28.67) and median time to tumor progression was 13.6 months (95% CI: 10.71-16.49). The most common hematological toxicity was neutropenia (no febrile neutropenia), which occurred in 28 patients (48.3%) but grade 3-4 in only 8 patients (14%). Alopecia, the most common nonhematological toxicity, occurred in 20 (34.5%) patients, but only 5 patients (8.6%) experienced grade 3 alopecia.
  
  
  CONCLUSIONS
  The activity of docetaxel and gemcitabine in metastatic breast cancer is confirmed. The promising results of the employed schedule, in agreement with other published studies, need to be further confirmed within a phase III study.
authors: Dipartimento di Oncologia, Cattedra di Oncologia Medica, Università di Palermo, Palermo, Italia. s_palmeri@libero.it
authors: S
authors: S
authors: Palmeri
authors: M
authors: M
authors: Vaglica
authors: S
authors: S
authors: Spada
authors: G
authors: G
authors: Filippelli
authors: A
authors: A
authors: Farris
authors: L
authors: L
authors: Palmeri
authors: B
authors: B
authors: Massidda
authors: A
authors: A
authors: Misino
authors: F
authors: F
authors: Ferraù
authors: G
authors: G
authors: Comella
authors: V
authors: V
authors: Leonardi
authors: G
authors: G
authors: Condemi
authors: A
authors: A
authors: Mangiameli
authors: G
authors: G
authors: De Cataldis
authors: M C
authors: MC
authors: Macaluso
authors: M
authors: M
authors: Cajozzo
authors: E
authors: E
authors: Iannitto
authors: M
authors: M
authors: Danova
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D006801:Humans; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine